Final study results show Pfizer’s experimental COVID-19 pill remained as effective as indicated by preliminary data last month, a major relief after promising data for …
Final trial data for molnupiravir were less convincing than what Merck previously reported and could alter how the FDA views the drug. New study results …
Pfizer is sharing rights to make its COVID-19 pill even as it closely guards the recipe for its coronavirus vaccine, which has mostly been supplied …
Pfizer’s pill is the second oral drug for COVID-19 to be proven strongly effective in large, placebo-controlled clinical trials after Merck’s molnupiravir, which early in …
Roche’s seeming lack of confidence in the future of AT-527 appears to be weighing on investors. Atea shares, which soared above $88 in February 2021, …
Merck is now in a race with Pfizer to capture the upside of COVID-19 pills, which could soon play an outsized role in the next …
Merck’s pill has the potential to alter the course of the pandemic. Earlier this month, the company and partner Ridgeback Biotherapeutics released data showing molnupiravir …
